UK-backed firm buys vaccine facility from Benchmark Holdings
Reuters
Published Jul 23, 2020 11:45
(Reuters) - A firm backed by the UK government has purchased a vaccine manufacturing facility from healthcare company Benchmark Holdings (L:BMKB) as the country ramps up efforts to produce potential coronavirus vaccines.
The London-listed company said on Thursday that Cell and Gene Therapy Catapult has bought its vaccine manufacturing facility at Braintree, UK for 16 million pounds in cash.
"This new ... centre, alongside crucial investment in skills, will support our efforts to rapidly produce millions of doses of a coronavirus vaccine while ensuring the UK can respond quickly to potential future pandemics," UK Business Secretary Alok Sharma said in a separate statement.
The deal is part of the UK government's 100-million-pound investment plan to boost its capacity to rapidly produce COVID-19 vaccines when they are available.
CGT Catapult is supported by Innovate UK.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.